查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2024542

微量殘存疾病）檢測市場規模：按技術、應用、最終用戶和地區分類（2026-2034 年）

Minimal Residual Disease Testing Market Size by Technology (Flow Cytometry, Polymerase Chain Reaction, Next Generation Sequencing, and Others), Application, End User, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 148 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球微量殘存疾病（MRD）檢測市場規模達25億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到58億美元，2026年至2034年的複合年成長率（CAGR）為9.32%。醫療保健產業的顯著成長、廣泛的研發活動以及技術的快速進步是推動該市場成長的關鍵因素。

微量殘存疾病）檢測是一種醫學檢測，用於檢測和監測癌症治療後患者體內可能殘留的少量癌細胞。它廣泛用於篩檢多種癌症，包括白血病、淋巴瘤、多發性骨髓瘤和某些固體癌。 MRD檢測採用高靈敏度技術，例​​如流式細胞技術、聚合酵素鏈鎖反應（PCR）和次世代定序（NGS）。這項重要的醫學檢測對於監測癌症患者、幫助醫生製定更合適的治療方案至關重要。 MRD檢測有助於早期發現疾病復發、更準確地評估治療反應、識別需要指導制定個人化治療方案的患者、改善患者預後並促進個人化治療方案的發展。

微量殘存疾病檢測市場的發展趨勢

全球癌症發生率的不斷攀升是推動市場成長的主要因素。微小殘留病灶（MRD）檢測是一種高靈敏度的技術，廣泛用於檢測殘留癌細胞，有助於早期識別疾病復發並指南個別化治療方案。因此，MRD檢測作為血液腫瘤（包括造血組織和免疫系統細胞來源的腫瘤）的診斷和監測工具的廣泛應用，正在推動市場成長。此外，消費者對個人化醫療的偏好轉變，使得個人化治療方案和監測成為可能，這也是推動市場成長的另一個因素。同時，人工智慧（AI）與MRD檢測的結合，能夠實現模式識別、復發可能性預測、提高診斷準確性和有效性，並幫助臨床醫生做出更明智的患者照護決策，正在加速市場成長。此外，新一代定序（NGS）技術的日益普及，透過對去氧核糖核酸（DNA）和核糖核酸（RNA）進行定序來研究疾病相關的基因變異，也為市場帶來了光明的前景。此外，大眾對識別體內致癌性重要性的認知不斷提高，也推動了市場成長。預計其他推動市場成長的因素包括醫療保健產業的顯著成長、廣泛的研發活動以及對微小殘留病灶（MRD）檢測專案領域的投資增加。

本報告解答的關鍵問題

  • 全球微量殘存疾病）檢測市場目前的發展狀況如何？未來幾年我們預計會看到哪些趨勢？
  • 全球微量殘存疾病）檢測市場的市場促進因素、限制因素和機會是什麼？
  • 各種促進因素​​、限制因素和機會如何影響全球微量殘存疾病）檢測市場？
  • 主要區域市場有哪些？
  • 哪個國家對微量殘存疾病檢測的需求市場最大？
  • 市場按技術分類是怎樣的？
  • 在微量殘存疾病）檢測市場中，哪種技術最具吸引力？
  • 按應用領域分類的市場區隔如何？
  • 在微量殘存疾病檢測市場中，最具吸引力的應用是什麼？
  • 依最終用戶分類的市場區隔如何？
  • 在微量殘存疾病檢測市場中，哪個終端用戶最具吸引力？
  • 全球微量殘存疾病）檢測市場的競爭格局如何？
  • 全球微量殘存疾病）檢測市場的主要參與企業/公司有哪些？

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球微量殘存疾病檢測市場（依技術、應用、最終用戶和地區分類）

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依技術分類

  • 流式細胞技術
  • 聚合酵素鏈鎖反應（PCR）
  • 下一代定序（NGS）
  • 其他

第7章 市場區隔：依應用領域分類

  • 骨髓惡性腫瘤
    • 主要部分
      • 白血病
      • 淋巴瘤
  • 固體癌

第8章 市場區隔：依最終用戶分類

  • 醫院和專科診所
  • 診斷實驗室
  • 學術研究機構
  • 其他

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章：促進、抑制與機遇

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Adaptive BIoTechnologies Corporation
    • Arup Laboratories Inc.
    • Bio-Rad Laboratories Inc.
    • Guardant Health
    • Invivoscribe Inc.
    • Natera Inc.
    • NeoGenomics Laboratories Inc.
    • Sysmex Corporation
Product Code: SR112026A7248

The global minimal residual disease (MRD) testing market size reached USD 2.5 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 5.8 Billion by 2034, exhibiting a growth rate (CAGR) of 9.32% during 2026-2034. Significant growth in the healthcare industry, extensive research and development (R&D) activities and rapid technological advancements represent some of the key factors driving the market.

Minimal residual disease (MRD) testing is a medical test used to detect and monitor small amounts of cancer cells that may remain in a patient's body after undergoing cancer treatment. It is widely used to test a variety of different types of cancer, such as leukemia, lymphoma, multiple myeloma, and some solid tumors. MRD testing uses highly sensitive methods, including cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS). It is an important medical test for monitoring cancer patients and helping doctors to make more informed treatment decisions. MRD testing helps in the early detection of disease recurrence, providing a more accurate assessment of treatment response and guiding personalized treatment planning by identifying patients, improving patient outcomes, and enhancing customized treatment planning.

Minimal Residual Disease (MRD) Testing Market Trends:

The increasing prevalence of cancer across the globe is one of the key factors driving the market growth. MRD testing is a highly sensitive technique that is widely used to detect residual cancer cells, which helps in an early indication of disease recurrence and helps guide personalized treatment planning. In line with this, the widespread adoption of MRD testing as a diagnostic and monitoring tool in hematological cancers that begin in blood-forming tissues or the cell of the immune system is favoring the market growth. Moreover, the shifting consumer preference toward personalized medicine that allows customized treatment planning and monitoring are acting as another growth-inducing factor. Apart from this, the integration of artificial intelligence (AI) with MRD testing that helps to identify patterns, predict the likelihood of recurrence, improve the accuracy and effectiveness of diagnosis, and help clinicians to make more informed decisions about patient care, is providing an impetus to the market growth. Additionally, the increasing adoption of NGS technology to determine the sequence of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) to study the genetic variations associated with the disease is creating a positive outlook for the market. Furthermore, growing awareness among people about the importance of identifying the presence of carcinogenic substances that can cause cancer in the body is propelling the market growth. Other factors, including significant growth in the healthcare industry, extensive research and development (R&D) activities, and increasing investments in the field of MRD testing programs, are anticipated to drive the market growth.

Key Market Segmentation:

The publisher provides an analysis of the key trends in each segment of the global minimal residual disease (MRD) testing market, along with forecasts at the global, regional, and country levels from 2026-2034. Our report has categorized the market based on technology, application, and end user.

Technology Insights:

  • Flow Cytometry
  • Polymerase Chain Reaction (PCR)
  • Next Generation Sequencing (NGS)
  • Others

Application Insights:

  • Hematological Malignancy
  • Leukemia
  • Lymphoma
  • Solid Tumors

End User Insights:

  • Hospitals and Speciality Clinics
  • Diagnostic Laboratories
  • Academic and Research Institutes
  • Others

Regional Insights:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for minimal residual disease (MRD) testing. Some of the factors driving the North America minimal residual disease (MRD) testing market included the increasing prevalence of cancer, significant growth in the healthcare industry, and extensive research and development (R&D) activities.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global minimal residual disease (MRD) testing market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Adaptive Biotechnologies Corporation, Arup Laboratories Inc., Bio-Rad Laboratories Inc., Guardant Health, Invivoscribe Inc., Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, etc.

Key Questions Answered in This Report:

  • How has the global minimal residual disease (MRD) testing market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global minimal residual disease (MRD) testing market?
  • What is the impact of each driver, restraint, and opportunity on the global minimal residual disease (MRD) testing market?
  • What are the key regional markets?
  • Which countries represent the most attractive minimal residual disease (MRD) testing market?
  • What is the breakup of the market based on technology?
  • Which is the most attractive technology in the minimal residual disease (MRD) testing market?
  • What is the breakup of the market based on the application?
  • Which is the most attractive application in the minimal residual disease (MRD) testing market?
  • What is the breakup of the market based on the end user?
  • Which is the most attractive end user in the minimal residual disease (MRD) testing market?
  • What is the competitive structure of the global minimal residual disease (MRD) testing market?
  • Who are the key players/companies in the global minimal residual disease (MRD) testing market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Minimal Residual Disease (MRD) Testing Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Technology

  • 6.1 Flow Cytometry
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Polymerase Chain Reaction (PCR)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Next Generation Sequencing (NGS)
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Hematological Malignancy
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Leukemia
      • 7.1.2.2 Lymphoma
    • 7.1.3 Market Forecast
  • 7.2 Solid Tumors
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals and Speciality Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Diagnostic Laboratories
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Academic and Research Institutes
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Adaptive Biotechnologies Corporation
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Arup Laboratories Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 SWOT Analysis
    • 14.3.3 Bio-Rad Laboratories Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Guardant Health
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Invivoscribe Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Natera Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 NeoGenomics Laboratories Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
    • 14.3.8 Sysmex Corporation
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Minimal Residual Disease Testing Market: Major Drivers and Challenges
  • Figure 2: Global: Minimal Residual Disease Testing Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Minimal Residual Disease Testing Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Minimal Residual Disease Testing Market: Breakup by Technology (in %), 2025
  • Figure 5: Global: Minimal Residual Disease Testing Market: Breakup by Application (in %), 2025
  • Figure 6: Global: Minimal Residual Disease Testing Market: Breakup by End User (in %), 2025
  • Figure 7: Global: Minimal Residual Disease Testing Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Minimal Residual Disease Testing (Flow Cytometry) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Minimal Residual Disease Testing (Flow Cytometry) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Minimal Residual Disease Testing (Polymerase Chain Reaction (PCR)) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Minimal Residual Disease Testing (Polymerase Chain Reaction (PCR)) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Minimal Residual Disease Testing (Next Generation Sequencing (NGS)) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Minimal Residual Disease Testing (Next Generation Sequencing (NGS)) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Minimal Residual Disease Testing (Other Technologies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Minimal Residual Disease Testing (Other Technologies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Minimal Residual Disease Testing (Hematological Malignancy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Minimal Residual Disease Testing (Hematological Malignancy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Minimal Residual Disease Testing (Solid Tumors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Minimal Residual Disease Testing (Solid Tumors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Minimal Residual Disease Testing (Hospitals and Speciality Clinics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Minimal Residual Disease Testing (Hospitals and Speciality Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Minimal Residual Disease Testing (Diagnostic Laboratories) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Minimal Residual Disease Testing (Diagnostic Laboratories) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Minimal Residual Disease Testing (Academic and Research Institutes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Minimal Residual Disease Testing (Academic and Research Institutes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Minimal Residual Disease Testing (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Minimal Residual Disease Testing (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: North America: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: North America: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: United States: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: United States: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Canada: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Canada: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Asia-Pacific: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Asia-Pacific: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: China: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: China: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Japan: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Japan: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: India: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: India: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: South Korea: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: South Korea: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Australia: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Australia: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Indonesia: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Indonesia: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Others: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Others: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Europe: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Europe: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Germany: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Germany: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: France: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: France: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: United Kingdom: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: United Kingdom: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Italy: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Italy: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Spain: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Spain: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Russia: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Russia: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Others: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Others: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Latin America: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Latin America: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Brazil: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Brazil: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Mexico: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Mexico: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Others: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Others: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Middle East and Africa: Minimal Residual Disease Testing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Middle East and Africa: Minimal Residual Disease Testing Market: Breakup by Country (in %), 2025
  • Figure 76: Middle East and Africa: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Global: Minimal Residual Disease Testing Industry: Drivers, Restraints, and Opportunities
  • Figure 78: Global: Minimal Residual Disease Testing Industry: Value Chain Analysis
  • Figure 79: Global: Minimal Residual Disease Testing Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Minimal Residual Disease Testing Market: Key Industry Highlights, 2025 & 2034
  • Table 2: Global: Minimal Residual Disease Testing Market Forecast: Breakup by Technology (in Million USD), 2026-2034
  • Table 3: Global: Minimal Residual Disease Testing Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 4: Global: Minimal Residual Disease Testing Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 5: Global: Minimal Residual Disease Testing Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Minimal Residual Disease Testing Market: Competitive Structure
  • Table 7: Global: Minimal Residual Disease Testing Market: Key Players